Morphic Holding saw the highest growth of 2.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Morphic Holding’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Morphic Holding has been focused on protecting inventions in Japan(JP) with three publications in Q2 2024
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 40% filings and 100% grants. The Japan(JP), United States(US), and Australia(AU) patent Office are among the top ten patent offices where Morphic Holding is filings its patents. Among the top granted patent authorities, Morphic Holding has 100% of its grants in Japan(JP).
Roche could be the strongest competitor for Morphic Holding
Inflammatory bowel disease related patents lead Morphic Holding portfolio followed by ulcerative colitis, and breast cancer
Morphic Holding has highest number of patents in inflammatory bowel disease followed by ulcerative colitis, breast cancer, hepatocellular carcinoma, and hypopharyngeal cancer. For inflammatory bowel disease, nearly 2% of patents were filed and 50% of patents were granted in Q2 2024.
For comprehensive analysis of Morphic Holding's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

